info@upfluorochem.com Chinese
Shanghai Up-Fluorochem Co., Ltd.
Hot Products
Remdesivir intermediate 2,3,5-Tri-O-benzyl-D-ribonolactone
Quaternium-15
Methyl 3-methoxyacrylate
3,3,3-Trifluoro-L-alanine
Sucrose octasulphate potassium salt
Sucrose octasulphate sodium salt
Current location:Home > News > BrowseNews

Promethera explores therapies for liver diseases in China

Date:2020-7-20 19:42:03Browse volume:Source of articles:biospectrum

image.png

Image credit- shutterstock.com

Belgium based Promethera Biosciences S.A., global innovator in cell-based medicines and liver diseases, and Hao Tian Development Group Limited, a diversified investment holding company, through its subsidiary Aceso Life Science Holding Limited have announced that the companies have entered into an agreement to form a joint venture.

Aceso and Promethera® hold 60% and 40% of the equity in the Joint Venture Company, respectively. The Joint Venture Company is vested with the exclusive right to develop, register, distribute and commercialize Promethera®'s therapeutic products (cell therapies and antibodies developed by Promethera® Group) in China and Southeast Asia.

Indications in which the products will be deployed include; Acute-on-Chronic Liver Failure (ACLF), Non-Alcoholic Steatohepatitis (NASH), Urea Cycle Disorder (UCD), liver cirrhosis and various autoimmune diseases and cancers.

Promethera® will manufacture and supply the therapeutic products, and provide ongoing technical support during development and commercialization. The Joint Venture Company will seek opportunities for cooperation with Itochu Corporation.

Hot News